Stock Price, Quote, News and Profile of ALDEYRA THERAPEUTICS INC(NASDAQ:ALDX) stock

ALDEYRA THERAPEUTICS INC

NASDAQ:ALDX (1/14/2025, 8:22:59 PM)

After market: 4.7 0 (0%)

4.7

-0.07 (-1.47%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%-78.57%

Sales Q2Q%N/A

CRS82.98

6 Month23.04%

Overview

Earnings (Last)11-07 2024-11-07/amc

Earnings (Next)N/A N/A

Ins Owners2.4%

Inst Owners44.82%

Market Cap279.88M

Shares59.55M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts88.57

Short Float %7.87%

Short Ratio7.96

IPO05-02 2014-05-02

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. The company is headquartered in Lexington, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2014-05-02. The firm's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.